Novartis patent bid rejected in India

An Indian court has rejected Novartis’ challenge of a law that denies patent protection to drugs that are only minor improvements to earlier drugs. Novartis’ challenge came after the Indian government allowed drug companies to make generic versions of the cancer drug Gleevec.

This is great news for consumers — both because it enables more people in the Third World to have access to affordable drugs, and because it encourages companies like Novartis to focus their R&D money on real innovation, rather than wasting valuable research dollars on gaming the system to extend patents.

More from Ed at Pharmalot.

About Cary Byrd

eDrugSearch founder, Cary Byrd, has been called an “e-health innovator” by MarketIntellNow, interviewed by top pharmaceutical industry journalists, invited to Matthew Holt’s Health 2.0 Conference and a Consumer Report's health summit, and highlighted on numerous health blogs.

eDrugSearch.com - Search. Compare. Save.

0 thoughts on “Novartis patent bid rejected in India

  • This is very good news not only for those living in third world countries but also for all those living in so called developed world. People living in developed countries are unaware that the pharmaceutical companies are looting them by making minor modification in the original form and charging them hefty premium. This ruling must be implemented by all countries.

Leave a Reply

Join Our Free Newsletter

Please enter email id

Get a weekly dose of money-saving tips on your medications, drug side effects alerts, drug interaction warnings, free prescription coupons, late-breaking safety information and much, much more!

Share via
Copy link